If you could not make it to EURETINA. Find the latest updates here!

Strong and sustained vision gains, proactive dosing Q8 and beyond2,3

EURETINA guidelines DME drug of choice in patients with baseline BCVA <69 letters4,a

In the Casselholm study, EYLEA® provided significantly reduced injection frequency by 24% vs. ranibizumab5,b,c

Strong, rapid, and sustained visual gains over 48 weeks6


Proactive dosing options across indications1

Mechanism of action

Unique, multi-targeted trap mechanism1,7

NEW in nAMD!

After 3 monthly EYLEA loading doses and one injection at Week 16, treatment can continue with proactive Q8 dosing or proactive treat-and-extend (T&E) dosing beyond Q81,d